Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
4.480
-0.170 (-3.66%)
At close: Sep 16, 2026, 4:00 PM EDT
4.460
-0.020 (-0.45%)
After-hours: Sep 16, 2026, 4:10 PM EDT
Coya Therapeutics Stock Forecast
Stock Price Forecast
According to 7 analysts polled by S&P Global, Coya Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $15.21. The average 1-year stock price forecast is 239.51% higher than the current stock price, while the lowest is $12 (+167.86%) and the highest is $18 (+301.79%).
Price Target: $15.21 (+239.51%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Coya Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 6 | 7 | 7 | 7 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 6 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $18 | Buy | Reiterates | $18 | +301.79% | Sep 9, 2026 |
| Roth MKM | Roth MKM | Buy Reiterates $4.87 → $12 | Buy | Reiterates | $4.87 → $12 | +167.86% | Aug 23, 2026 |
| BTIG | BTIG | Buy Maintains $16 | Buy | Maintains | $16 | +257.14% | Aug 12, 2026 |
| Lake Street | Lake Street | Buy Maintains $17 | Buy | Maintains | $17 | +279.46% | May 22, 2026 |
| Chardan Capital | Chardan Capital | Buy Maintains $14 | Buy | Maintains | $14 | +212.50% | May 13, 2026 |
Financial Forecast
Revenue This Year
1.02M
from 7.95M
Decreased by -87.18%
Revenue Next Year
4.96M
from 1.02M
Increased by 387.14%
EPS This Year
-1.37
from -1.27
EPS Next Year
-1.88
from -1.37
EPS and Forward PE are based on non-GAAP adjusted numbers.